Market closed

Merus/$MRUS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Ticker

$MRUS
Trading on

Industry

Biotechnology

Employees

201

Merus Metrics

BasicAdvanced
$2.9B
Market cap
-
P/E ratio
-$3.98
EPS
1.09
Beta
-
Dividend rate
$2.9B
1.09
$61.61
$25.68
623K
8.321
7.944
1.32
1.571
-21.59%
-44.60%
72.062
4.1
4.11
-16.46
-21.33%
9.59%
-6.11%
20.96%

What the Analysts think about Merus

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Merus stock.

Merus Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merus Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRUS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Merus stock?

Merus (MRUS) has a market cap of $2.9B as of December 21, 2024.

What is the P/E ratio for Merus stock?

The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of December 21, 2024.

Does Merus stock pay dividends?

No, Merus (MRUS) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Merus dividend payment date?

Merus (MRUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Merus?

Merus (MRUS) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.